BCL2 and B-cell chronic lymphocytic leukemia: In a recent phase III study, presented at the ASH meeting 2023, a significantly improved response in CLL patients treated with a combination of ibrutinib and the BCL2 inhibitor venetoclax was observed with a 3-year PFS rate of 97.2% and an ORR of 95.4% (95% CI, 92.1-97.6%) (Table 1).